BioWorld Asia

Dec. 22, 2010

EpiTherapeutics, Abbott in Epigenetics Oncology Deal

EpiTherapeutics ApS, which is developing cancer drugs based on epigenetics targets, entered its first drug discovery pact, with Abbott, of Abbott Park, Ill. (BioWorld International) Read More

Xention Spins Out Provesica to Advance Bladder Drug

Genomics of Lung Cancer Yields a New Drug Target

NovImmune Tops Off Cash with $20M for Antibody Trials

Two Biotechs Merge to Form PsiOxus Therapeutics

Proximagen Picks up GSK's Discarded CNS Programs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...